Sanofi's Nexviazyme Meets Primary Goal in Phase 3 Study for Infantile-Onset Pompe Disease
Sanofi's Phase 3 Baby-COMET study showed Nexviazyme improved ventilator-free survival in infants with infantile-onset Pompe disease, supporting plans for a US regulatory filing to expand the therapy's approved indication.
Genetic Disorder | 01/07/2026 | By News Bureau | 130
Pint Pharma Announces Approval of ORLADEYO in Peru
Pint Pharma has announced that the General Directorate of Medicines Supplies and Drugs (DIGEMID) in Peru has announced the approval of ORLADEYO (berotralstat) for prophylaxis of hereditary angioedema (HAE) attacks in adults and children 12 years and older.
Genetic Disorder | 10/07/2024 | By Aishwarya | 742
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy